595917 The disclosure relates to co-administration a compound of formula I (R7227) a NS3/NS4A protease inhibitor with a cytochrome P450 inhibitor wherein the cytochrome P450 inhibitor is ritonavir, to elevate the blood levels of the compound of formula I. The use of these compositions to treat Hepatitis C (HCV) is also disclosed.